Filing Details
- Accession Number:
- 0001140361-14-045154
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-12 19:11:21
- Reporting Period:
- 2014-12-10
- Filing Date:
- 2014-12-12
- Accepted Time:
- 2014-12-12 19:11:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1416792 | Relypsa Inc | RLYP | Pharmaceutical Preparations (2834) | 260893742 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1283972 | Dr R Klaus Veitinger | C/O Relypsa, Inc. 700 Saginaw Drive Redwood City CA 94063 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-12-10 | 4,167 | $4.65 | 6,879 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-12-10 | 800 | $30.38 | 6,079 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-12-10 | 3,104 | $31.52 | 2,975 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-12-10 | 263 | $32.20 | 2,712 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2014-12-11 | 150 | $4.65 | 2,862 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-12-11 | 150 | $32.50 | 2,712 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2014-12-12 | 9,852 | $4.65 | 12,564 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-12-12 | 9,852 | $32.50 | 2,712 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2014-12-10 | 4,167 | $0.00 | 4,167 | $4.65 |
Common Stock | Stock Option (right to buy) | Disposition | 2014-12-11 | 150 | $0.00 | 150 | $4.65 |
Common Stock | Stock Option (right to buy) | Disposition | 2014-12-12 | 9,852 | $0.00 | 9,852 | $4.65 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
37,796 | 2020-10-31 | No | 4 | M | Direct | |
37,646 | 2020-10-31 | No | 4 | M | Direct | |
27,794 | 2020-10-31 | No | 4 | M | Direct |
Footnotes
- Includes 2,712 restricted stock units.
- The sales reported in this Form 4 were effected pursuant to the Reporting Person's personal Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.80, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.06 to $32.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $32.06 to $32.29, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.